anti-CEA, mAb (37B6)

Product description: Carcinoembryonic antigen (CEA) was first described in 1965 by Gold and Freedman when they identified an antigen that was present in both fetal colon and colon adenocarcinoma but that appeared to be absent from healthy adult colon. CEA is a glycoprotein containing approximately 50% carbohydrate with a molecular weight of 180 kDa. CEA and related genes make up the CEA family belonging to the immunoglobulin superfamily. In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. CEA has proven to be a suitable target antigen for the detection of primary and metastatic colorectal and some other carcinomas. Although sera from healthy individuals and from patients with other diseases generally had low levels of CEA, CEA is one of the most widely used tumor markers worldwide. Its main application is mostly in gastrointestinal cancers, especially in colorectal malignancy. CEA assays are now generally accepted clinically as a useful and cost-efficient tool in monitoring of colon cancer following surgery. Cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. Receptor for E.coli Dr adhesins.

Alternate Names/Synonyms: CEA; CD66e; CEACAM5; Meconium Antigen 100; Carcinoembryonic Antigen; Carcinoembryonic Antigen-related Cell Adhesion Molecule 5

Product Type: Monoclonal Antibody

Clone: 37B6

Isotype: Mouse IgG1 kappa

Immunogen: Human native protein.

Applications: ELISA, IP, WB

Species Crossreactivity: Human

Formulation: Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.

Long Term Storage: -20°C

Shipping: BLUE ICE

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.

Lien vers la Fiche Technique